Triple threat: new cocktail takes on recurrent ovarian cancer
NCT ID NCT07239622
First seen Nov 20, 2025 · Last updated Jun 10, 2026 · Updated 35 times
Summary
This study tests a combination of three drugs—liposomal irinotecan, sintilimab, and anlotinib—in people whose ovarian clear cell carcinoma has come back or not gone away after standard treatment. The goal is to see if this mix can shrink tumors and control the disease. About 36 adults aged 18 to 75 will take part, receiving the drugs in 3-week cycles. This is not a cure, but aims to manage the cancer and slow its growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.